[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 2016

The Role of Clozapine in Treatment-Resistant Schizophrenia

Author Affiliations
  • 1Department of Psychiatry and Molecular Medicine, Zucker Hillside Hospital, North Shore–Long Island Jewish Health System, Glen Oaks, New York
  • 2Hofstra North Shore–LIJ (Long Island Jewish) School of Medicine, Hempstead, New York
  • 3Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, New York
JAMA Psychiatry. 2016;73(3):187-188. doi:10.1001/jamapsychiatry.2015.2966

In this issue of JAMA Psychiatry, the study by Samara et al1 provides an important update on the evidence surrounding clozapine as the treatment of choice for those individuals with schizophrenia that is considered resistant to other medications. The authors indicate that as many as one-third of patients with schizophrenia experience persistent psychotic symptoms despite adequate treatment with antipsychotics. Therefore, the management of schizophrenia in these patients represents a major public health challenge in human and economic terms.

First Page Preview View Large
First page PDF preview
First page PDF preview
×